Notice to Prescribers Concerning the Carve-Out of Naloxone

On October 1, 2014, injectable naloxone hydrochloride (generic version of Narcan® and Evzio®) was carved-out of the HealthChoice managed care benefit and is now covered by Medicaid fee-for-service. The carve-out of naloxone hydrochloride injections joins the mental health drugs and antiretroviral agents as other drugs that are carved-out from the HealthChoice managed care benefit and are covered by Medicaid fee-for-service.

The carve-out of these naloxone products will have no effect on the way you would normally prescribe injectable naloxone. A prescription is required in order for your patient to receive injectable naloxone. However, if you wish to prescribe an Intranasal (IN) Mucosal Atomizing Device that can be used as an alternative route of the administration of naloxone, then a separate prescription will be required in order for the pharmacy to dispense the device. The separate prescription is needed because the device is classified as a Durable Medical Equipment (DME) needle free injection device and is billed by the pharmacy separately from the prescription for naloxone.